Rodec Pharma Ltd. IPO Details
Rodec Pharma was incorporated on November 18, 1997. The company is engaged in manufacturing animal feed supplements and marketing veterinary pharmaceutical products to meet the healthcare and nutritional needs of livestock. Its product portfolio is specifically designed to support animal health and overall productivity
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.7 M | - | - | ₹0 | DRHP DOC |
Rodec Pharma issue details
Rodec Pharma has 5.7 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Rodec Pharma IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Rodec Pharma NUMBER OF SHARES ON OFFER
Rodec Pharma FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| H1FY26 | 62.7 | 9.7 | 1.1 | 0.8 | 21.4% |
| FY25 | 106.4 | 18.3 | 8.9 | 6.4 | 24.2% |
| FY24 | 88.4 | 11.0 | 9.0 | 5.6 | 17.8% |
| FY23 | 71.6 | 5.2 | 10.6 | 5.2 | 11.3% |
Rodec Pharma INFORMATION ON IPO ISSUE
About Rodec Pharma
Rodec Pharma was incorporated on November 18, 1997. The company is engaged in manufacturing animal feed supplements and marketing veterinary pharmaceutical products to meet the healthcare and nutritional needs of livestock. Its product portfolio is specifically designed to support animal health and overall productivity
Object of the Issue
- To carry out the offer for sale of upto 56,50,000 equity shares of face value of Rs 10 each by the promoter selling shareholder
- To achieve the benefits of listing the equity shares on stock exchanges
Rodec Pharma - PROMOTERS
| Name |
|---|
| Mukesh Kumar Gupta |
| Chhaya Gupta |
| Utkarsh Gupta |
Rodec Pharma - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Mukesh Kumar Gupta | Managing Director |
| Chhaya Gupta | Whole Time Director |
| Utkarsh Gupta | Non- Executive Director |
| Achal Kapoor | Independent Director |
| Nikita Sinha | Independent Director |
| Preeti | Independent Director |
Rodec Pharma Book Running Lead Manager
Khambatta Securities Limited
ipo@khambattasecurities.com
Rodec Pharma Registrar to the Offer
Bigshare Services Private Limited
ipo@bigshareonline.com
Rodec Pharma Strengths
Diversified product portfolio
The company has developed a diverse portfolio of 35 veterinary pharmaceutical products with 29 variants across categories such as antibiotics, antiparasitics, and animal feed supplements. This broad range positions it as a comprehensive solutions provider, enabling revenue diversification and reducing dependence on any single product
Qualitative products
The company manufactures animal feed supplements at its Fami-QS and ISO-certified facility, following strict quality control measures at every stage of production. It also ensures rigorous quality checks for third-party manufactured products and follows a structured development process focused on identified therapeutic needs and effective product formulation
Partnerships & collaborations
The company has partnered with Bluejais B.V., Netherlands, as its exclusive dealer in India to strengthen its presence in the poultry segment through enhanced market access and distribution. This strategic collaboration enables efficient market penetration, improved competitiveness, and capital-efficient expansion in a rapidly growing poultry market
Rodec Pharma Risks
Handling risks
The company’s operations require strict storage and handling of raw materials and finished products, as improper conditions may lead to damage, spoilage, or loss of efficacy. Limited storage facilities and deviations in temperature, humidity, or pest control could adversely affect product quality, safety, and shelf life
Counterparty credit risk
The company faces counterparty credit risk due to extending credit to customers, which may impact cash flows if receivables are delayed or not collected. Despite setting credit limits based on customer profiles, payment defaults or delays could adversely affect financial performance and operations
Regulatory risks
The company’s operations are subject to environmental, health, safety, labour, and other regulatory requirements, and any non-compliance could adversely impact its business and financial performance. These regulations govern manufacturing, testing, labeling, marketing, and employee safety for animal feed supplements and veterinary pharmaceutical products
IPO FAQs
The promoters of the company are Mukesh Kumar Gupta, Chhaya Gupta and Utkarsh Gupta.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.